Saundra L. Pelletier - Feb 18, 2022 Form 4 Insider Report for Evofem Biosciences, Inc. (EVFM)

Role
Chief Executive Officer, Director
Signature
/s/ Justin J. File, attorney-in-fact
Stock symbol
EVFM
Transactions as of
Feb 18, 2022
Transactions value $
$0
Form type
4
Date filed
2/23/2022, 03:04 PM
Previous filing
Jan 4, 2022
Next filing
May 31, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EVFM Common Stock Award $0 +750K +109.36% $0.00 1.44M Feb 18, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVFM Stock option (right to buy) Award $0 +750K $0.00 750K Feb 18, 2022 Common Stock 750K $0.49 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2022.
F2 The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 18, 2022.